Here are four other recent updates from the vaccine-maker:
1. The company has 48 programs in development, including 36 in ongoing clinical studies.
2. It projects spending $4.5 billion in 2023 on research and development.
3. On Jan. 4, the company said it would acquire genomics company OriCiro for $85 million.
4. Moderna will collaborate with an oncology business to investigate potential therapeutic options for mRNA, the technology used in its COVID-19 vaccine.
